-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T+lQn8zO57UAYjDgD7l2hGUso4HZpqbtdxyAIh9KRHpnODAQ7+6Y0VDi7gGR1oJD
 vl0vy5Qq0tG2A3A5l/hfzQ==

<SEC-DOCUMENT>0001075880-05-000005.txt : 20050118
<SEC-HEADER>0001075880-05-000005.hdr.sgml : 20050117
<ACCEPTANCE-DATETIME>20050118060558
ACCESSION NUMBER:		0001075880-05-000005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20050118
FILED AS OF DATE:		20050118
DATE AS OF CHANGE:		20050118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		05531903

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050118.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 18 January,2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
18 JANUARY, 2005

NOVOGEN REACHES SETTLEMENT WITH GNC ON ISOFLAVONE PATENT
INFRINGEMENT CASE.

STAMFORD, CT., January 18, 2005  - Novogen Limited (Nasdaq: NVGN),
the world leader in Isoflavone Research, has settled, for an
undisclosed amount and terms, the legal action it had taken
against the General Nutrition Corporation ("GNC").

The lawsuit alleged that certain menopause products sold under
the GNC brand infringed one of Novogen's US  patents
(US Patent No. 6,562,380).

In addition to an undisclosed monetary settlement GNC has
agreed to reinstate the sale of  Promensil, Novogen's leading
consumer product of red clover isoflavones for the relief of
menopausal symptoms, through GNC's retail outlets.  GNC is a
retailer of health food supplements in the US with 4800 retail
outlets and 1300 franchise stores.

The Chief Executive of Novogen, Mr Christopher Naughton, said
Novogen was dedicated to the development of isoflavonoid technology,
protected by intellectual property, in both the dietary supplement
and prescription pharmaceutical arenas.

"The resolution of this matter is significant recognition of the
value of our isoflavone patent portfolio," Mr Naughton said.

Novogen manages its international research and development
programs utilising the expertise and clinical research capabilities
of universities and hospitals in the US, Australia and other
key international locations.

The Company markets a range of dietary supplement products based
on isoflavones derived from red clover.  Its leading dietary
supplement products are Promensil, for the relief of menopausal
symptoms, and Trinovin, for prostate health.

Novogen's anti-cancer drug phenoxodiol is currently in Phase II
human clinical trials in the US and Australia.  The rights to
commercialise this drug are licensed to the Company's majority owned
subsidiary, Marshall Edwards, Inc., which is listed on both
NASDAQ (MSHL) and the London Stock Exchange's
Alternate Investment Market (MSH).

More information on the Novogen group of companies
and their associated technology developments can be
found at www.novogen.com and at www.marshalledwardsinc.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
